Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination. Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide. TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a transformative biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurological, metabolic, and alcohol misuse disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling Quantum BioPharma to immediately advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical development.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
Quantum BioPharma has achieved a significant milestone with the FDA approval of its IND application for Lucid-MS, initiating the Phase 2 clinical trial. This innovative, patented neuroprotective therapy aims to address the pressing needs in the multi-billion dollar progressive MS market.
- FDA Clearance: Unlocks the potential for groundbreaking treatment in progressive MS.
- Phase 2 Study: Randomized, double-blind, placebo-controlled design enhances reliability.
- Targeted Approach: Focuses on demyelination, a primary concern in multiple sclerosis.
Why it matters: The successful advancement of Lucid-MS could transform treatment options for millions affected by progressive multiple sclerosis.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.